TITLE

Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)

AUTHOR(S)
García-Cabeza, Ignacio; Gómez, Juan-Carlos; Sacristán, Jose A.; Edgell, Eric; De Chavez, Manuel González
PUB. DATE
January 2001
SOURCE
BMC Psychiatry;2001, Vol. 1, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: In order to compare the effectiveness of different antipsychotic drugs in the treatment of schizophrenia it is very important to evaluate subjective response and compliance in patient cohorts treated according to routine clinical practice. Method: Outpatients with schizophrenia entered this prospective, naturalistic study when they received a new prescription for an antipsychotic drug. Treatment assignment was based on purely clinical criteria, as the study did not include any experimental intervention. Patients treated with olanzapine, risperidone or haloperidol were included in the analysis. Subjective response was measured using the 10-item version of the Drug Attitude Inventory (DAI-10), and treatment compliance was measured using a physician-rated 4 point categorical scale. Results: A total of 2128 patients initiated treatment (as monotherapy) with olanzapine, 417 with risperidone, and 112 with haloperidol. Olanzapine-treated patients had significantly higher DAI-10 scores and significantly better treatment compliance compared to both risperidone- and haloperidol-treated patients. Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients. Conclusion: Subjective response and compliance were superior in olanzapine-treated patients, compared to patients treated with risperidone and haloperidol, in routine clinical practice. Differences in subjective response were explained largely, but not completely, by differences in incidence of EPS.
ACCESSION #
29323609

 

Related Articles

  • Risperidone-induced reversible neutropenia. Kailasam, Vasanth Kattalai; Chima, Victoria; Nnamdi, Uchechukwu; Sharma, Kavita; Shah, Kairav // Neuropsychiatric Disease & Treatment;Jul2017, Vol. 13, p1975 

    This case report presents a 44-year-old man with a history of schizophrenia who developed neutropenia on risperidone therapy. The patient's laboratory reports showed a gradual decline of leukocytes and neutrophils after resolution and rechallenging. This was reversed with the discontinuation of...

  • Practical Issues with Amisulpride in the Management of Patients with Schizophrenia. Pani, Luca; Villagrán, José M.; Kontaxakis, Vassilis P.; Alptekin, Köksal // Clinical Drug Investigation;2008, Vol. 28 Issue 8, p466 

    Amisulpride is an atypical antipsychotic with a significantly greater effect size than first-generation, typical antipsychotics, and efficacy at least similar to that of olanzapine and risperidone in large-scale clinical trials in schizophrenia. Amisulpride provides greater improvement in...

  • Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder. Gigante, Alexandre Dnarte; Lafer, Beny; Yatham, Lakshmi N. // CNS Drugs;2012, Vol. 26 Issue 5, p403 

    Depot antipsychotics have been used as a strategy to reduce non-adherence to medications in schizophrenia and bipolar disorder (BD). This article reviews the literature on the efficacy and safety of first- and second-generation depot antipsychotics (FGDA and SGDA, respectively) for the...

  • Safety and Tolerability: How Do Newer Generation “Atypical” Antipsychotics Compare? Tandon, Rajiv // Psychiatric Quarterly;Dec2002, Vol. 73 Issue 4, p297 

    Previously, clinicians worked with antipsychotic drugs that almost invariably caused extrapyramidal side effects (EPS) at the dose at which they were clinically effective. By definition, all newer generation atypical antipsychotic agents are significantly better than conventional agents with...

  • Quantitative Psychomotor Dysfunction in Schizophrenia: A Loss of Drive, Impaired Movement Execution or Both? Docx, Lise; Sabbe, Bernard; Provinciael, Pieter; Merckx, Niel; Morrens, Manuel // Neuropsychobiology;2013, Vol. 68 Issue 4, p221 

    Aims: The aim of the present study was to investigate the predictive value of qualitative psychomotor performance levels and subaspects of the negative syndrome for quantitative motor activity levels in patients with schizophrenia. Methods: Twenty-seven stabilized patients with schizophrenia and...

  • Association of Typical versus Atypical Antipsychotics with Symptoms and Quality of Life in Schizophrenia. Fujimaki, Koichiro; Takahashi, Terumichi; Morinobu, Shigeru // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Background: Several reports on patients with chronic schizophrenia suggest that atypical versus typical antipsychotics are expected to lead to better quality of life (QOL) and cognitive function. Our aim was to examine the association of chronic treatment with typical or atypical antipsychotics...

  • The promise of new drugs for schizophrenia treatment. Tamminga, C. A.; Tamminga, Ca // Canadian Journal of Psychiatry;Apr1997, Vol. 42 Issue 3, p265 

    Objective: To present aspects of preclinical and clinical pharmacology of new antipsychotic drugs and to emphasize those preclinical drug characteristics which might predict desirable clinical actions.Method: Review of the relevant literature and publicly presented...

  • Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection. Asseburg, Christian; Willis, Michael; Löthgren, Mickael; Seppälä, Niko; Hakala, Mika; Persson, Ulf // Schizophrenia Research & Treatment;2012, p1 

    Objectives: Quantify changes in hospital resource use in Finland following initiation of risperidone long-acting injection (RLAI). Materials and Methods: A retrospective multi-center chart review (naturalistic setting) was used to compare annual hospital bed-days and hospital episodes for 177...

  • Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia. Barteček, Richard; Kašpárek, Tomáš; Češková, Eva // Central European Journal of Medicine;Oct2011, Vol. 6 Issue 5, p662 

    Withdrawal-emergent adverse effects of antipsychotics are an infrequently identified condition which can appear during antipsychotic dose reduction and medication change. In this paper, we present the case of severe extrapyramidal symptoms after a dose reduction of risperidone is presented. A...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics